Background

Acute Myeloid Leukemia (AML) is an aggressive and heterogeneous cancer characterized by abnormal differentiation of myeloid blood cells. While considerable advancements in AML treatment have been made, the long-term survival rate of AML is still less than 50% in younger patients and only around 15% for older adults today. A key challenge is that surviving leukemic cells contribute to relapse post-chemotherapy, but little is known about these enduring leukemic cells and how they reinitiate disease, leading to a lack of methods to monitor disease post-intervention and lack of therapies to combat AML relapse.